MedTrace Logo

Clinical Investigation to Evaluate the Effectiveness and Safety of ECG App

NCT05482503 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 673

Last updated 2022-08-02

No results posted yet for this study

Summary

The purpose of this study is to verify the effectiveness and safety of the Huawei Device software (ECG APP), which can be used to analyze, store and display the ECG data transmitted by the single-lead ECG acquisition device. The software can be used for the analysis of sinus rhythm, atrial fibrillation, and premature beats(ventricular premature beats and atrial premature beats) in adults.

Conditions

  • Arrhythmias, Cardiac

Interventions

DEVICE

12-Lead ECG(I-lead)

All participants will simultaneously record 12-lead ECGs(I-lead)

Sponsors & Collaborators

  • Huawei Device Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Guo Yutao, doctor · The First Medical Center of the Chinese PLA General Hospital & Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-02
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05482503 on ClinicalTrials.gov